Treatment approved for young children with severe eosinophilic asthma
Nucala is the first biologic approved in the US for six- to 11-year-old children with severe eosinophilic asthma by the FDA.
List view / Grid view
News
Purdue Pharma files for bankruptcy protection in the US
Purdue has filed for bankruptcy protection after a settlement offer from the company over the opioid crisis was rejected by 24 states.
NDMA discovered in samples of ranitidine medicines
The EMA and the FDA are investigating some ranitidine medicines after they were found to contain NDMA, a probable human carcinogen.
Kenya launches phased malaria vaccine pilot programme
Kenya has become the third African country to introduce the world’s first malaria vaccine into the country, in a phased pilot programme.
FDA emphasises need for adverse event reporting of compounded drugs
The FDA says that even though it recognises the importance of compounded drugs, they also pose a risk to patient safety.
FDA grants regulatory approval for hypoglycemia treatment
GVOKE injection has received regulatory approval from the FDA for the treatment of severe hypoglycemia in patients with diabetes.
Germany imports largest ever shipment of EU medicinal cannabis
An import of medicinal cannabis from Portugal to Germany signifies the largest quantity ever moved within the EU, highlighting a surge in the medicinal cannabis products market.
UK to launch seven data hubs to garner insights for improved healthcare
The seven centres will aid disease research and clinical development, improving access to patient data for studies.
Purdue reported to reach tentative agreement over opioid trial
A settlement has purportedly been agreed between Purdue Pharma and 23 US states to resolve the opioid crisis case against the company.
Blockchain technology in healthcare market to hit $1.6bn by 2025
According to a new report, blockchain technology in the healthcare market size is set to increase exponentially.
Operation Yellowhammer file confirms drug shortages after no-deal Brexit
The Operation Yellowhammer document has been published, which states that the UK will experience severe delays to the medical supply chain following a no-deal Brexit.
FDA grants Orphan Drug Designation to sotatercept
Orphan Drug Designation has been given to sotatercept for the treatment of patients with pulmonary arterial hypertension.
Metastatic NSCLC therapy, tepotinib, given Breakthrough Designation
Tepotinib, an investigational therapy for patients with metastatic non-small cell lung cancer has been given Breakthrough Therapy Designation.
Innovative Medicines Canada files against federal plans
The lobbying group Innovative Medicines Canada has announced its lawsuit against plans to lower drug prices in the country.
Bacteriostatic Water recalled due to a potential lack of sterility assurance
Bacteriostatic Water is being recalled because of a lack of sterilisation confirmation for some vials.
